Research ArticleSupplement
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann and Frederik L. Giesel
Journal of Nuclear Medicine September 2017, 58 (Supplement 2) 67S-76S; DOI: https://doi.org/10.2967/jnumed.116.186767
Matthias Eiber
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Wolfgang P. Fendler
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
3Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany
Steven P. Rowe
4Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland
Jeremie Calais
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California
Michael S. Hofman
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Tobias Maurer
6Department of Urology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Sarah M. Schwarzenboeck
7Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany
Clemens Kratowchil
8Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; and
Ken Herrmann
9Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Germany
Frederik L. Giesel
8Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; and
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue Supplement 2
September 1, 2017
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann, Frederik L. Giesel
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 67S-76S; DOI: 10.2967/jnumed.116.186767
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratowchil, Ken Herrmann, Frederik L. Giesel
Journal of Nuclear Medicine Sep 2017, 58 (Supplement 2) 67S-76S; DOI: 10.2967/jnumed.116.186767
Jump to section
Related Articles
- No related articles found.
Cited By...
- Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
- The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
- PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
- Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement
- Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
- Lymph Node Involvement in Treatment-Naive Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
- Prostate-Specific Membrane Antigen-Guided Surgery
- 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
- The Future of Nuclear Medicine as an Independent Specialty
- qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux
- Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer
- Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
- One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer
- A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
- Proposed Criteria Positions PSMA PET for the Future
- Theranostic Concepts: More Than Just a Fashion Trend--Introduction and Overview